Glaxosmithkline plc, of London, presented data at the CDC's Advisory Committee on Immunization Practices meeting in Atlanta that Fluarix Quadrivalent demonstrated 63.2 percent efficacy against moderate to severe influenza and 49.8 percent efficacy against influenza of any severity in children 6 months through 35 months of age.